
Sham Mailankody
Articles
-
Sep 18, 2024 |
nature.com | Malin Hultcrantz |Hani Hassoun |Neha Korde |Kylee H. Maclachlan |Sham Mailankody |Urvi A. Shah | +9 more
Letter to the EditorLenalidomide is an immunomodulatory drug that is recommended and widely used as part of induction therapy and maintenance for multiple myeloma (MM) [1]. Lenalidomide maintenance is associated with significantly improved progression-free and overall survival, as shown in several clinical trials and meta-analyses [2,3,4,5,6,7]. Most patients tolerate lenalidomide well; however, fatigue and diarrhea are common side effects in the maintenance phase [3, 7, 8].
-
Jun 24, 2024 |
targetedonc.com | Sham Mailankody
Case: A 70-Year-Old Man with Early Relapse Multiple MyelomaClinical Presentation:A 70-year-old man who was diagnosed 5 years ago with R-ISS stage 2/R2-ISS stage III lenalidomide refractory IgG-kappa multiple myeloma presents to his oncologist after two prior treatment regimens. Lives in a rural communityPMH: hypertension controlled with lisinopril. Prior Treatments:Patient received previous treatments with:D-VRd followed by ASCT with lenalidomide maintenance. Achieved VGPR, post-ASCT.
-
May 30, 2024 |
nature.com | Andriy Derkach |Bruno Costa |David Chung |Heather Landau |Oscar B. Lahoud |Hani Hassoun | +8 more
AbstractB-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates (ADC). The primary endpoint was severe (grade ≥3) infection incidence. Amongst 256 patients, 92 received CAR-T, 55 BsAb and 109 ADC.
-
Jul 25, 2023 |
nature.com | Carlyn Tan |Andriy Derkach |Malin Hultcrantz |Sham Mailankody |Urvi A. Shah |Kylee H. Maclachlan | +7 more
AbstractLenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly diagnosed multiple myeloma, 198 received VRd and 191 received KRd. Median PFS was not reached (NR) in both groups; 5-year PFS was 56% (95%CI, 48–64%) for VRd and 67% (60–75%) for KRd (P = 0.027).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →